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Introduction
The issue of antibiotic resistance in bacteria is growing. For example, methicillin-resistant Staphylococcus
aureus (MRSA) is a leading human pathogen. New strains of MRSA are resistant to methicillin and numerous
other antibiotics, placing the patient in signiﬁcant danger. Indeed, the Centers for Disease Control revealed in
2007 that the number of deaths due to MRSA exceeded that of AIDS in the United States. It is no wonder that
antibiotic resistance is one of the most signiﬁcant and important health care issues. The ability of bacterial
pathogens to evade traditional antibiotics is faster than the drug makers’ ability to make new types of clinical
drugs.1
Evolutionary biologists have seized upon this rapid phenotypic change as alleged powerful evidence for
Darwinian evolution. Thus, antibiotic resistance is an important two-fold issue involving empirical medical
science and the volatile origins issue. It is frequently cited as a fact of evolution. Most recently, Carl Zimmer,
in his new book, Microcosm: E. coli and the New Science of Life, uses drug resistance in Escherichia coli to
bolster his arguments for macroevolution (or molecules-to-man evolution). One of his chapters, “Darwin at the
Drugstore,” states that scientists are investigating drug resistance in E. coli to demonstrate their ability to
undergo “rapid bursts of evolution”.2 Many biologists argue a case for Darwinian medicine—using evolutionary
explanations to describe the wide variation in antibiotic resistance and adaption to new drugs.
Antibiotic resistance is certainly an example of change, but it is hardly a fact of macroevolution (bacteria
remain bacteria). Creation microbiologist, Dr. Kevin Anderson, states that such variation in bacteria is
beneﬁcial for their survival outcome in a clinical environment, but not a beneﬁcial mutation. Anderson goes on
to demonstrate how some “ﬁtness” cost is often associated with mutations, although reversion mutations may
eventually recover most, if not all, of this cost for some bacteria.3 A biological cost does occur in the loss of preexisting cellular systems or functions. Such loss of cellular activity cannot legitimately be offered as a genetic
means of demonstrating macroevolution.
Creation biologists have long been interested in discussing antibiotic resistance but have frequently cited
other scientists’ data to make generalizations about drug-resistant bacteria being less ﬁt overall than wild-type
bacteria.4 Although this principle is theoretically simple to state on paper, experiments demonstrating ﬁtness
costs have been quite tricky in practice. In some cases, creation biologists have interpreted the data well; in
other cases they have made wide, sweeping generalizations without data to back up their assertions.
Purpose of Study
In an on-going study at Liberty University, antibiotic resistance in the common red bacteria, Serratia
marcescens, is being investigated to evaluate biological cost to bacteria due to resistance. The major objective
of these experiments was to test the hypothesis that ampicillin-resistant bacteria are less “ﬁt” than their wildtype counterparts. The investigation focused on the most common clinical, ampicillin-resistant S. marcescens
strains (WFR) and compared with a wild-type strain. We evaluated the inﬂuence of ampicillin resistance on the
bacteria’s overall ﬁtness in a non-clinical environment.
Serratia marcescens is a Gram-negative, rod-shaped, facultative anaerobe (ﬁg. 1), is ubiquitous in soil and
water, and therefore is a common contaminant of food. It is easily grown in the lab and may serve as an ideal
model for competition studies because of the natural color variation of S. marcescens.5 In the wild, S. marcescens
is noted for the production of a bright red pigment called prodigiosin.6 In contrast, 95% of clinical, resistant
strains of Serratia are white or have little pigment.7
S. marcescens is also a common cause of nosocomial (hospital) infections of the digestive and urinary tracts.8
In fact, 92% of all S. marcescens pathogens isolated from clinical settings have acquired ampicillin resistance.9
The WF strain of Serratia marcescens was ﬁrst isolated at the Texas Medical Center and has continued in the
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laboratory of Robert Williams for decades. This strain
was chosen because it has characteristics like the vast
majority of clinical strains (113/114 strains examined
by Ding and Williams).10
In our study, we compared the biological ﬁtness of
Serratia marcescens strains that are red, ampicillinsensitive (AMPS) versus white, ampicillin resistant
(AMPR). We wanted to ascertain whether antibiotic
resistant mutants are less ﬁt than wild-type. Fitness
was deﬁned by growth rate and colony “robustness” in
minimal media.
Minimal Media Simulates Famine Conditions
Initially, it was difﬁcult to demonstrate differences
between wild-type and clinical strains in a rich media
(Nutrient or Typticase-soy agar). There were no
Fig. 1. Phenotypic variation in Serratia marcescens can differences in growth rate or colony size. However, after
vary among red, pink, white, and other colors
switching to minimal media and observing hourly, the
differences were readily observed. In order to conﬁrm and extend the differences in growth rates between the
sensitive BS303S strain (isolated from pond water) and the resistant WFR strain, a ﬁtness/competition assay was
performed. This assay sought to simulate famine conditions in the natural environment by utilizing minimal
media and to evaluate the wild-type against ampicillin resistant, clinical strains exhibiting loss of prodigiosin
production. Once subjected to conditions that were “harsh,” differences were seen in their performance (growth
rate and robustness of colonies).

Bacteria numbers
(Absorbance at 620mm)

The Results Show a Difference
One analogy to explain the need to use minimal media in competition studies is the way in which weeds, not
lush grass, grow during times of heat and drought. Like most people, we like a green lawn ﬁlled with robust,
cultivated grass. During the spring when temperatures are moderate and plenty of rain comes, green grass
grows well, along with a few weeds. However, during the summer, the maintenance of a good lawn is difﬁcult:
after a month of “drought,” clover and dandelions take over. The cultivated, green grass corresponds to antibioticresistant bacteria that have grown in the laboratory or (hospital-like environments), and the weeds represent the
wild-type bacteria. In the spring, cultivated grasses, clover, and dandelions all grow nicely together producing
a good lawn. When nutrients and proper temperature are maintained, both wild-type and resistant bacteria
grow nicely in the Petri dish and in the body. But as conditions turn harsh, only the more ﬁt bacteria (wildtype) grow well. Therefore, in order to simulate competition in the wild, bacteria must be grown on minimal
media. Minimal media mimics better
what bacteria experience in a natural
Growth rates of wild-type BC303 AmpS vs. WF AmpR
Serratia marcescens
environment over a period of time. This is
0.8
the place where ﬁtness can be accurately
assessed. Given a rich media, they grow
0.7
BS303
about the same (data not shown).
Sensitive
0.6
Sensitive and resistant S. marcescens
WF Resistant
show differences in growth rate. The
0.5
greatest apparent differences observed were
at 4 and 6 hours (ﬁg. 2). When comparisons
0.4
were made between wild-type and mutant
0.3
strains at other times, differences in growth
rate were not measurably different. The
0.2
experiments suggest ampicillin resistance
0.1
has a metabolic cost to the S. marcescens
strains. At least in minimal media, this
0
claim is true.
0
2
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The largest differences in growth rates
among Serratia strains (BS303S and WFR) Fig. 2. Comparisons of WF R (white, ampicillin-resistant) vs. BS 303
were observed between 4 and 6 hours (ﬁg. (red, wild-type). Note differences at 4 and 6 hours.
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2). BS303S after four hours had 51% and after six hours had 35% more growth than WFR. As incubation
time increased, WFR caught up to BS303S, in terms of cell numbers. At the end of 10 hours post inoculation,
there was only a 4% difference between BS303S and WFR. The wild-type BS303S also had larger colonies
(data not shown). Thus, slower growth rates observed in the ampicillin-resistant, clinical strains compared to
the ampicillin-sensitive, wild-type strains, demonstrate that due to this mutation, the bacteria experienced a
decrease in net cellular function.
These results demonstrate that wild-type BS303S has a signiﬁcant ﬁtness advantage over the mutant strains
due to its growth rate and colony size. Therefore, it can be argued that ampicillin resistance mutations reduce
the growth rate and therefore the general biological ﬁtness of S. marcescens. This study concurs with Anderson
that while mutations providing antibiotic resistance may be beneﬁcial in certain, speciﬁc environments, they
often come at the expense of pre-existing function, and thus do not provide a mechanism for macroevolution.11
It should be noted that we have found similar results with another Serratia marcescens clinical strain (933)
and have observed it in E. coli. These ﬁndings will be reported in future papers. Our experience with competition
studies reveals that demonstrating ﬁtness costs in the laboratory is tricky and creation biologists should be
careful about making dogmatic statements like, “Wild-type bacteria always outcompete antibiotic resistant
mutants in nature.” Some bacteria that have an antibiotic resistance gene integrated into their chromosome
can make compensatory mutations, over multiple, successive generations. These resistant bacteria compete
favorably with wild-type bacteria in nature given certain environmental conditions.12, 13
Conclusions
Darwinian evolutionists attempt to offer explanations on antibiotic resistance and prescriptions for future drug
development. If they simply suggest an awareness of on-going changes in pathogenic bacteria, we would concur.
Bacteria do acquire resistance quickly, and many older drugs no longer work in hospitals and clinics. Creation
microbiologists are interested in ﬁnding new drugs that will work and seek to heal the sick (Luke 10:9).
If evolutionists mean that one type of bacteria will “evolve” into another type, we would disagree based
upon the evidence. A conclusion of these experiments is that acquiring antibiotic resistance through mutation
or horizontal transfer is “costly.” There is a tradeoff: for survival in a clinical environment (that is, antibiotics
prevalent), there is a metabolic cost in terms of slower growth. This is called antagonistic pleiotropy. Antagonistic
pleiotropy refers to the genetic expression of multiple competing effects, some beneﬁcial, but others harmful to
the organism. It often involves a case where reproduction and viability counter each other in biological ﬁtness.14
The gene provides a beneﬁt in one circumstance, but has cost in another.
The results of various experiments do show that bacteria can change quickly. Although the acquisition of
antibiotic resistance does not demonstrate Darwinian evolution, it does demonstrate that bacteria were endowed
by their Creator to change and adapt very quickly in an almost constantly changing environment. Bacteria
have tremendous variability, yet there are limits to such change: the continuity, stability, and reliability of such
bacteria are well known.
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